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1. INTRODUCTION 
The answer of biological systems to any external stimulus is now 
a well known physiological mechanism, starting from procariotic cells 
to superior organisms. However, the molecular mechanisms by which 
a biological system integrates external stimuli are much more 
complicated then expected. It is clear now that the genome 
dynamically integrates signals coming from the extracellular 
environment. Every cell follows a specific genetic program that 
establishes which genes have to be activated and transcribed and 
which have to be silenced. Such a genetic program is able to 
dynamically regulate itself in response to the environmental stimuli. 
This dynamic contest is due to specific molecular marks that cells 
use to generate signals of information that can be recognized and 
read by committed protein complexes. Such molecular marks target 
covalently not only the genome (the DNA sequence), but also other 
protein components such as histones. Taken together, DNA 
sequence and protein components represent the chromatin which 
undergoes several dynamic covalent modifications triggering or 
inhibiting specific biological processes as modulation of gene 
transcription. Such dynamic changes of the genetic program can be 
inherited during cell division and represent the epigenome. 
Thus, the epigenetic modifications are the means by which cells 
manage the genetic program interpreting the external stimuli.  
 
1.1 DNA methylation and its biological role 
Symmetric methylation of cytosine in CpG dinucleotides is one of 
the widespread modifications in animal genomes. To date, this 
modification has been found both in invertebrates (Drosophila 
melanogaster) (Hung et al., 1999) and in chordates (from Ciona 
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intestinalis to mammals) (Simmen et al., 1999). It has been 
associated with an inactive chromatin state (heterochromatin) and, 
therefore, as negative regulator of transcription. It is now well known 
that DNA methylation plays an important role in epigenetic regulation 
of gene expression that is not directly dependent on primary structure 
of DNA, but is maintained by several protein or non-protein factors 
such as histone tail modifications and chromosome territory. It is 
generally accepted that DNA methylation is a unidirectional process. 
If any sequence acquires CpG methylation then this modification 
becomes stable and will be inherited after cell division. So, both 
daughter DNA molecules will have same pattern of methylation.  
DNA methylation affects gene expression directly or indirectly. 
Some transcriptional factors (i.e. Sp1) can interact only with non-
methylated DNA sequences, whereas methylation of cytosine 
abolishes interaction (Clark et al., 1997). This in turn leads to less 
effective transcription of certain genes. On the other hand, there is a 
different mechanism of action of CpG methylation. MBD (methyl-
DNA-binding domain) proteins (Hendrich and Bird 1998) specifically 
recognize and bind methylated DNA sequences and attract large 
protein complexes that can change chromatin conformation from 
“opened” to “closed”. 
DNA methylation occupies up to 70% of the CpG dinucleotides in 
the genome, and represents likely the major epigenetic modification 
in mammals (Robertson and Wolffe, 2000). The organization of the 
mammalian genome is such that there is a high density of CpG in the 
upstream promoter regions in most of the approximately 30,000 
genes, as well as within gene introns and exons (Bird, 2002). This 
organizational feature and the capacity for DNA methylation to 
silence transcription in mammals lead to the early speculation that 
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gene regulation might be highly sensitive to the methylation status of 
these so-called CpG islands (Holliday and Pugh, 1975). However, 
this proved not to be the case, as these potential targets for 
methylation were found to be unmethylated, at least for most genes 
under normal circumstances (Antequera and Bird, 1993; reviewed in 
Meehan and Stancheva, 2001). Notable exceptions to this general 
rule include imprinted genes and those of the inactive X-
chromosome. Further genomic characterization identified other 
classes of sequence families with significant levels of CpG, leading to 
alternative proposals for the significance of this stable and heritable 
modification. The mammalian genome contains an extremely high 
burden of sequences that have arisen due to integration of 
retrotransposons. Uncontrolled expression of these sequences from 
their viral promoters would result in transcriptional chaos, were it not 
for the susceptibility of these promoters to be repressed by DNA 
methylation (Yoder et al., 1997). This regulatory role for DNA 
methylation has been embodied in the genome defense hypothesis, 
and remains one of the significant functions of DNA methylation 
(Walsh et al., 1998). 
One of the most comprehensively studied roles of DNA 
methylation is the marking of parental alleles by genomic imprinting. 
Imprinted genes are expressed in a non-Mendelian fashion, in which 
parent-of-origin specifies the active allele (Reik and Walter, 2001). 
These genes are essential for fetal growth and development, and 
have been shown to also influence postnatal growth trajectories and 
diverse biological processes, for example, affecting thermogenesis in 
offspring, maternal care and suckling behavior, and adult behavior 
and cognition (Li et al., 1999; Plagge et al., 2004). The marking of the 
active and inactive alleles is achieved through differential DNA 
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methylation in critical regulatory regions. These differentially 
methylated regions (DMRs) are essential for expression or 
repression. It is interesting to note that a disproportionately high 
number of imprinted genes are found to be methylated on the 
maternal allele (Reik and Walter, 2001). 
During development in mammals, there are at least two periods 
of genome-wide DNA methylation reprogramming (Reik and Walter, 
2001). The two periods best characterized include a time during 
primordial germ cell differentiation and one during preimplantation 
development. The extent of this reprogramming and whether, in fact, 
it is required for normal development in all mammalian species 
remain unknown (Bestor, 2000). In this regard, the details of DNA 
methylation reprogramming in humans are only just beginning to be 
appreciated. The degree to which this important regulatory 
mechanism operates in early development and germ cell 
differentiation in humans will influence our understanding of the 
potential impact of DNA methylation in human health and disease. 
A growing body of evidence indicates that DNA methylation, 
together with chromatin modifications, are competent to specify 
transcriptional states and perhaps more importantly, mutually 
reinforce transcriptionally repressive states (Tamaru and Selker, 
2001; Fuks et al., 2003; Tamaru et al., 2003). Also, epigenetic 
regulation of gene expression includes processes as embryonic 
development, transcription, chromatin structure, X chromosome 
inactivation, genomic imprinting and chromosome stability. Consistent 
with these important roles, a growing number of human diseases 




1.2 The DNA-methyltransferases 
Introduction of the methyl group into the symmetrical dinucleotide 
5-CpG-3 results in its positioning into the major groove of the DNA 
without interference with the base-pairing of nucleotides. Methylation 
of cytosine residues imposes a greater level of risk to the stability of 
the genome as deamination of methyl-cytosine results in the 
transition of meC-T, a nucleotide base change less easily repaired 
and recognized than the deamination of cytosine to uracil (Hermann 
et al., 2004). The lack of high fidelity repair capacity for the meC-T 
transition explains the observation that CG sites are a major 
mutational hotspot, accounting for up to 30% of point mutations in the 
germline, and are decidedly underrepresented in mammalian 
genomes (Bird et al., 1985). This situation suggests that the 
maintenance of this modification and its functions have been the 
result of considerable evolutionary pressure, and that the continued 
maintenance of cytosine methylation must confer a significant 
advantage given the substantial costs. The complexity of DNA 
methylation in the genome suggests that there must be a number of 
activities responsible for its establishment and maintenance, able to 
operate in both specialized and generalized functions (Chen et al., 
2003).  
DNA methyltransferases (MTases) represent a collection of three 
family groups numbered in order of their discovery (Bestor, 2000). 
These enzymes serve the two distinctive processes of DNA 
methylation, the establishment of DNA methylation state by de novo 
methylation and, thereafter, the maintenance of those states by 
templating this information to daughter strands arising from 
replication (Lei et al., 1996; Okano et al., 1999). Despite some 
sequence similarities, the divisions of labor amongst this group can, 
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in part, be inferred by their functional organization. Broadly, their 
organization can be resolved into two functional domains; the N-
terminal domain comprising regulatory functions and the C-terminal 
catalytic domain (Fig.1) (Bestor, 2000; Robertson, 2002). 
Dnmt1 was the first of the group of MTases identified, and is the 
largest of these activities with an extensive N-terminal regulatory 
domain and a smaller C-terminal domain (Bestor et al., 1988). This 
large regulatory domain contains a wide variety of functional motifs, 
including a nuclear localization signal, a proliferating cell nuclear 
antigen (PCNA) (Chuang et al., 1997) interacting domain, and a 
replicating foci targeting region (Leonhardt et al., 1992). Dnmt1 does 
not function in the cell in an isolated manner, and is capable of 
interacting with many proteins via the N-terminus. This interaction is 
likely to be facilitated by the polybromo domain (PBHD), a hallmark of 
protein-protein interaction (Bestor and Verdine, 1994). Furthermore, 
this domain has been implicated in a transport role for Dnmt1 to the 
replication foci (Liu et al., 1998). Dnmt1 methylates DNA specifically 
at CG sites, with a strict preference for hemimethylated over 
unmethylated substrates in vitro (Pradhan et al., 1997, 1999). It is this 
preference for hemimethylated substrates that forms the basis for its 
function as a maintenance methylase. In this respect, it is not 
surprising that Dnmt1 expression is tightly coordinated with DNA 
replication. In addition to its function as a MTase, Dnmt1 has been 
shown to be associated with a wide variety of chromatin modifying 
activities, including histone methyltransferases, methyl CpG binding 
proteins, and heterochromatin binding protein HP1 (Hermann et al., 
2004). Collectively, these associations share in common the 
properties of transcriptional repressors leading to the understanding 
that Dnmt1 and, hence, DNA methylation stably reinforces chromatin 
 7 
silencing (Bird, 2002). Also this enzyme is required for the survival of 
the organism as its knock out is lethal in embryos (reviewed in 
Jaenisch and Bird, 2003). 
The Dnmt2 gene is the most highly conserved of the MTases in 
eukaryotes, found in both organisms that show methylation and those 
that have no detectable DNA methylation. Although it is ubiquitously 
expressed at low levels in most human and mouse tissues as well as 
mouse embryonic stem cells, mice homozygous for a Dnmt2 null 
mutation are viable, and display normal levels of methylation at 
endogenous sequences (Okano et al., 1998b). Introduction of an 
inducible transgene containing Dnmt2 indicated that a genuine 
methylase activity could be demonstrated, albeit on CpT and CpA 
targets (Kunert et al., 2003). A weak but reproducible in vivo 
methyltransferase activity was recently demonstrated for the 
recombinant protein in mammalian cell lines (Liu et al., 2003). 
Dnmt3 family. The highly related enzymes, Dnmt3a and 
Dnmt3b, are encoded by different genes but share the preference for 
methylation of unmethylated CG dinucleotides. This substrate 
preference identifies them as de novo DNA methylases (Okano et al., 
1998a). Dnmt3a and Dnmt3b are thought to differ mechanistically due 
to inherent differences in the catalytic domains, suggesting that 
Dnmt3a is distributive while Dnmt3b is processive (Gowher and 
Jeltsch, 2002). These intrinsic differences allow for an effective 
division of labor between these related de novo methylases. The 
processive Dnmt3b is more suited to methylation of CG-rich regions 
of the genome, such as the CG-rich pericentromeric repeats 
(Hermann et al., 2004). The distributive nature of Dnmt3a requires 
that it adds back methylation to dinucleotides on a target by target 
basis, and is thus implicated in de novo methylation at single genetic 
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loci (Hata et al., 2002). A specific function for Dnmt3a was not 
detectable with the knockout model but studies using the various 
Dnmt-knockout ES cells in addition to transgenic Drosophila 
melanogaster expressing Dnmt3a revealed that this enzyme may be 
specialized to methylate non-CpG sequences like CpA, and CpT 
although the function of non-CpG methylation in ES cells is unknown 
(Ramsahoye et al., 2000). Dnmt3a is the major form in adult tissues, 
where it colocalizes with heterochromatin. In contrast, the isozyme 
Dnmt3a2 is the major form during embryogenesis, and has been 
shown to localize with euchromatin (Chen et al., 2002). Both Dnmt3a 
and Dnmt3b are required for the survival of an adult organism: lack of 
Dnmt3b is embryonic lethal and lack of Dnmt3a lethal in mice of few 
weeks (Okano et al., 1999, reviewed in Robertson KD, 2005). 
The third significant member of the Dnmt3 family of enzymes is 
Dnmt3L. This highly degenerate protein shows clear homology to 
Dnmt3a and Dnmt3b, but despite conserved folding like MTases, 
Dnmt3L lacks any catalytic activity but is expressed together with 
Dnmt3a and Dnmt3b during gametogenesis and embryogenesis 
(Bourc'his et al., 2001; Hata et al., 2002). Dnmt3a and Dnmt3L are 
essential for establishment of imprinted regions in oocytes (Hata et 
al., 2002). The exact mechanism of this process is not fully worked 
out, but there is the suggestion that the sequence specific function of 
Dnmt3a may require an activator to enforce the accuracy of this 
targeting. In this regard, Dnmt3L may function as an activator protein 








1.3 The methyl-binding proteins: linking DNA methylation 
and chromatin structure 
A. Bird identified the first methyl-DNA-binding activity called 
MeCP1 (methyl-CpG-binding protein 1) (Meehan et al., 1989). This 
activity included two complexes (400 and 800 kD) consisting of 
different components. It was shown that MeCP1 plays an important 
role in regulation of expression of reporter genes if these genes had 
methylated promoter regions. Then a protein called MeCP2 was 
identified (Lewis et al., 1992). It had a number of biochemical and 
functional characteristics different from MeCP1. For example, its 
molecular weight was about 50 kD and only one symmetrically 
methylated CpG was sufficient for specific interaction of MeCP2 with 
DNA sequence (MeCP1 needed 12 symmetrically methylated CpGs). 
It was shown that an 85-amino-acid domain in the N-terminal part of 
protein was responsible for interaction with methylated DNA. This 
domain was called MBD (methyl-DNA-binding domain). An analogous 
domain was found for MBD1 protein (formerly PCM1). 
In 1998, Hendrich and Bird published a paper about identification 
and characterization of a family of methyl-DNA-binding proteins 
(Hendrich and Bird 1998). Three new proteins MBD2, MBD3, and 
MBD4 were described in addition to previously characterized MBD1 
and MeCP2. Expression of all MBD proteins was found in almost all 
somatic tissues. Moreover, methyl-specific interaction with DNA and 
co-localization with constitutive heterochromatin were shown for 





MeCP2 is a protein with molecular weight of about 50 kD. It has 
two functional domains - MBD and TRD (transcription repression 
domain). TRD is necessary for interaction of MeCP2 with the 
mSin3A/HDAC nucleosome remodeling complex and plays crucial 
role in repression of transcription of target genes. The N-terminal 
domain (MBD) is responsible for interaction with methylated DNA 
and, as previously stated, only one symmetrically methylated CpG is 
sufficient for specific interaction of MeCP2 with DNA sequence. 
However, the flanking sequences may influence the binding as shown 
by Cheng et al., 2003. MeCP2 can also interact with other 
transcriptional factors and co-repressors (like SMRT) (Klose and Bird, 
2004). The mRNA coding for MeCP2 is present in all adult somatic 
tissues tested. Recently, Zhou et al., showed that calcium influx 
membrane-depolarization dependent during synaptic activity triggers 
phsphorylation on serine 423 of MeCP2 by CaMKII. This 
posttranslational modification attenuates its repressor activity 
promoting BDNF (brain-developed neurotrophic factor) transcription 
(Zhou et al., Neuron 2006). MeCP2 is the most intensively studied 
MBD protein because defects (i.e. point mutations) in MeCP2 gene 
are the cause of Rett syndrome (RTT). RTT is an X-linked dominant 
disease; it is a progressive neurologic developmental disorder and 
one of the most common causes of mental retardation in females. 
Patients appear to develop normally until 6 to 18 months of age, then 
gradually loss of speech and purposeful hand movements and 
develop microcephaly, seizures, autism, ataxia, intermittent 
hyperventilation, and stereotypic hand movements. After initial 
regression, the condition stabilizes and patients usually survive into 
adulthood. Also, conditional brain-specific deletion of this gene leads 
to generation of symptoms analogous to symptoms of Rett syndrome 
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(Johnston et al., 2003). Some of these symptoms are mental 
retardation, heavy breathing, stereotyping, increased tone, 
macroorchidism, memory dysfunctions such as manic depressive 
psychosis and impairments in adaptative behaviour. 
MBD1 is the largest member of the MBD family. It consists of 
~640 amino acid residues and has molecular weight ~75 kD. MBD1 
interacts with DNA in a methylation-dependent manner in EMSA 
experiments. But it can repress either methylated or non-methylated 
transitory transfected constructs. Moreover, MBD1, unlike MBD2 and 
MBD4, can co-localize with regions of constitutive heterochromatin 
even in cell with aberrant DNA methylation maintenance system (i.e., 
without DNMT1) (Hendrich and Bird 1998). In early works, only two 
functional domains of MBD1 were described-MBD and a domain 
consisting of three CxxC-motifs (homologous to motifs found in DNA-
methyltransferase DNMT1), but another domain was described quite 
soon. This domain (TRD, by analogy to transcriptional repression 
domain of MeCP2) is involved in transcriptional repression of reporter 
constructs as well as one of the CxxC-motifs (Ng et al., 2000). It was 
shown at the same time that MBD1 can utilize different functional 
domains for interaction with different proteins. For example, TRD is 
important for interaction with MCAF (MBD1-containing chromatin-
associated factor) (Fujita et al., 2003a). Complexes Suv39h1-
HP1alpha (Fujita et al., 2003b) and p150-CAF-HP1 (Reese et al., 
2003) interact with the MBD domain. MBD1 can also interact with 
SETDB1 histone-methyltransferase. Protein p150-CAF was 
characterized as a partner of MBD1 in a yeast two-hybrid screen. 
Complex CAF (chromatin associated factor) takes part in nucleosome 
assembly after DNA replication and maintenance of active/inactive 
chromatin state. One of three subunits of this complex, p150, 
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interacts with HP1 protein and is involved in maintenance of inactive 
heterochromatin. Moreover, p150-CAF can interact with PCNA 
(proliferating cell nuclear antigen) during DNA replication. PCNA, in 
turn, interacts with DNMT1. p150-CAF attracts MBD1-SETDB1 
complex that leads to methylation of lysine 9 of histone H3 and to 
formation of inactive chromatin. 
MBD2 and MBD3 are related proteins. There is a hypothesis 
that genes coding these factors diverged from a common precursor. 
The genes have common exon-intron structure and amino acid 
sequences of MBD2 and MBD3 are identical by 70% (Hendrich et al., 
1999a). But despite these similarities, MBD2 and MBD3 have 
different functions. MBD3 is a structure subunit of one of the major 
chromatin-remodeling complexes-NuRD (nucleosome remodeling 
and histone deacetylase complex) (Zhang et al., 1999), whereas 
MBD2 is only one of the DNA-binding subunits of MeCP1 (Ng et al., 
1999). Knockout of MBD3 leads to embryonic lethality in mice 
immediately after implantation of the embryo (Hendrich et al., 2001). 
Deletion of MBD2 does not have such serious consequences. 
Moreover, there are no abnormalities either in imprinting/X-
inactivation or repression of mobile elements in MBD2-/- mice. There 
is only one phenotypic effect of knockout of MBD2-abnormal maternal 
behavior (Hendrich et al., 2001).  
MBD4 is a protein with molecular weight ~60 kD having two 
functional domains-MBD and a glycosylase domain. MBD4 co-
localizes with regions of constitutive heterochromatin and can bind 
methylated DNA in vitro, but despite other MBD-proteins does not 
participate in regulation of gene expression. This protein belongs to 
the mismatch repair system. Methylated cytosines are so-called “hot 
spot” of mutagenesis they can be converted to thymines after 
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spontaneous deamination. MBD4 is involved in processes of 
recognition and correction of such mutations (Hendrich et al., 1999b). 
Deletion of MBD4 leads to accumulation of mutations and higher 
frequency of carcinogenesis (Miller et al., 2002). 
Kaiso is a unique methyl-DNA-binding protein. It does not have 
classical methyl-DNA-binding domain and interacts with DNA via a 
zinc finger domain consisting of three zinc fingers of C2H2 type. 
Another functional domain of Kaiso is the N-terminal 120 amino acid 
BTB/POZ-domain (Prokhortchouk et al., 2001). This domain is 
usually located in the N-terminal part of BTB-proteins and serves for 
homo- or heterodimerization during protein-protein interactions. Most 
BTB-proteins are transcriptional repressors. Kaiso was initially 
identified by a yeast two-hybrid screen as a partner of p120-catenin 
which is an important predominantly cytoplasmic protein interacting 
with and stabilizing E-cadherin (Davis et al., 2003). It was also shown 
that Kaiso is a component of double MeCP1 complex. It is a part of a 
rapidly migrating band called Kaiso-generated band (KGB) 
(Prokhortchouk et al., 2001). The molecular weight of KGB is 
~700 kD. There is a possibility that Kaiso-containing complex serves 
as an effector in signal-transduction pathway from cell membrane to 
nucleus and is responsible for repression of target genes in response 
to extracellular signals. 
However, the activity of methyl-binding proteins likely depends 
on their association with different molecular partners. One example of 
a multiple function methyl-binding protein is MBD2. MBD2 exerts 
different activities depending on its association with different partners. 
MBD2 can be a component of a large protein complex, MeCP1, 
which represses transcription from densely methylated genes. 
MeCP1 includes HDAC1, HDAC2, and RbAp46/48 proteins (Ng and 
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Bird 1999; Ng et al., 1999). By this way, MBD2 targets deacetylase 
activity at methylated sites. MBD2 can also recruit on methylated 
DNA a different corepressor complex, Mi-2/NuRD, through its 
hetrodimerization with MBD3 (Hendrich et al., 2001; Bowen et al., 
2004). Other authors have identified a protein, MIZF, that associates 
with MBD2 and significantly enhances HDAC proteins recruitment 
and activity (Sekimata et al., 2001). In addition, MBD2 form a 
complex with DNA methyltransferase 1 (DNMT1) on hemimethylated 
DNA at replication foci and may help to establish or maintain the 
repressed state of chromatin (Tatemat et al., 2000). While the above 
described functions result in transcriptional repression, recently it is 
emerging that when MBD2 associates with other partners, it may 
have opposite effects resulting in transcriptional activation of 
methylated genes. In a recent study, it was shown that the viral 
protein Tax can activate transcription from the methylated HTLV-1 
long terminal repeat (LTR) through the interaction with MBD2 (Ego et 
al., 2005).  The transcription factor GATA-3 can displace MBD2 from 
a methylated promoter causing the transcriptional reactivation of 
GATA-3 responsive genes (Hutchins et al., 2002). 
We recently described a novel MBD2 associating protein, 
MBDin, showing the unique ability to reactivate MBD2-repressed 
genes still in methylated status (Lembo et al., 2003). In the case of 
MBDin-mediated reactivation, as well as for GATA-3, transcriptional 
reactivation occurs prior to demethylation. However, MBDin is 
recruited by MBD2 on methylated DNA and acts by interfering with 
the ability of MBD2 to associate with the repressor complex rather 
than through displacement of MBD2 from methyl-CpG sites (Lembo 
et al., 2003). Recently it has been shown that MBD2 interacts with 
RNA helicase A, a component of CREB transcriptional co-activator 
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complex (Fujita et al., 2003). All these mechanisms lead to activation 
of methylated genes not through a possible active demethylase 
function of MBD2, but rather, through the association of MBD2 with a 
variety factors that can be recruited on methylated DNA and 
determine different interpretations of DNA methylation signals. 
We have also recently described another unrelated MBD2 
interactor, TACC3, displaying a similar activity on methylated genes. 
MBD2/TACC3 form a complex in vivo with the histone 
acetyltransferase pCAF. MBD2 could also associate with HDAC2, a 
component of MeCP1 repression complex. However, we found that 
complexes formed by MBD2 with TACC3/pCAF and with HDAC2 
were mutually exclusive (Angrisano et al., 2006). Moreover, HAT 
enzymatic assays demonstrated that HAT activity associates with 
MBD2 in vivo and that such association significantly increased when 
TACC3 was over-expressed (Angrisano et al., 2006). Thus, TACC3 
can be recruited by MBD2 on methylated promoters and is able to 
reactivate transcription possibly by favouring the formation of a HAT-
containing MBD2 complex and, thus, switching the repression 
potential of MBD2 in activation (Angrisano et al., 2006). 
 
1.4 Chromatin, histone code hypothesis and Code-readers 
The basic unit of chromatin is the nucleosome core particle, 
which contains 147 bp of DNA wrapped nearly twice around an 
octamer of the core histones. Each of the core histones has a related 
globular domain that mediates histone–histone interactions within the 
octamer, and that organizes the two wraps of nucleosomal DNA. The 
histone octamer is composed of a central heterotetramer of histones 
H3 and H4, flanked by two heterodimers of histones H2A and H2B. 
Each nucleosome is separated by 10–60 bp of ‘linker’ DNA, and the 
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resulting nucleosomal array constitutes a chromatin fiber of 10 nm in 
diameter. Also, each histone harbours an amino-terminal 20–35 
residue segment that is rich in basic amino acids and extends from 
the surface of the nucleosome; histone H2A is unique in having an 
additional 37 amino acid carboxy-terminal domain that protrudes from 
the nucleosome. These histone ‘tails’ do not contribute significantly to 
the structure of individual nucleosomes nor to their stability, but they 
do play an essential role in controlling the folding of nucleosomal 
arrays into higher-order structures. This simple ‘beads-on-a-string’ 
arrangement is folded into more condensed, 30 nm thick fibers that 
are stabilized by binding of a linker histone to each nucleosome core. 
Such 30 nm fibers are then further condensed in vivo to form 100–
400 nm thick interphase fibers or the more highly compacted 
metaphase chromosome structures (Fig.2). Indeed, in vitro removal 
of the histone tails results in nucleosomal arrays that cannot 
condense past the beads-on-a-string 10 nm fibre (reviewed in Mellor, 
2006). 
Such an organized DNA/Protein structure, which is called 
chromatin, carries not only genetic information encoded in the DNA 
component but also epigenetic information carried by histone proteins 
in the form of reversible covalent modifications. The function of 
different chromatin structures depends on a large number of post-
translational covalent modifications occurring on specific chromatin 
components, with different modifications yielding distinct functional 
consequences. Most of these modifications occur at the unstructured 
histone “tails” that are predicted to protrude between the gyres of 

































In fact, histones are subject to an enormous number of post-
translational modifications, including acetylation and methylation of 
lysines (K) and arginines (R), phosphorylation of serines (S) and 
threonines (T), ubiquitylation and sumoylation of lysines, as well as 
ribosylation. 
Adding to the complexity is the fact that each lysine residue can 
accept one, two or even three methyl groups, and an arginine can be 
either mono- or di-methylated. The majority of these post-translational 
marks occur on the amino-terminal and carboxy-terminal histone tail 
domains, although more and more examples of modifications within 
the central domains of the histones have been identified. Given the 
number of new modification sites that are identified each year, it 
seems likely that nearly every histone residue that is accessible to 
solvent may be a target for post-translational modification. These 
modifications may regulate access to the DNA and thus influence 
nuclear processes, such as transcription. Accumulating evidence 
suggests that these modifications are part of a histone code and that 
they act as highly selective binding platforms for the association of 
specific regulatory proteins. Such proteins have the ability to read 
the code and modify, directly or indirectly, the chromatin structure. 
In recent work, high-resolution chromatin immunoprecipitation 
has revealed distinct distributions and associations for the different 
modifications throughout the genome. For example, methylated lysine 
9 (K9) or K27 on histone H3 are generally associated with genes 
whose transcription is repressed, whereas methylated K4, K36, and 
K79 are found in active chromatin. Also, the combination of H4 K8 
acetylation, H3 K14 acetylation, and H3 S10 phosphorylation is often 
associated with transcription. Conversely, the lack of H3 and H4 
acetylation correlates with transcriptional repression in higher 
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eukaryotes. Moreover, “active” marks show distinct distributions over 
transcribed genes. The trimethylated form of K4 (K4me3) is found at 
the 5′ region of active genes together with acetylated lysines. By 
contrast, K36me3 generally accumulates toward the 3′ region of 
active genes that is also associated with deacetylated lysines.  
Particular patterns of histone modifications also correlate with global 
chromatin dynamics, as diacetylation of histone H4 at K4 and K12 is 
associated with histone deposition at S phase, and phosphorylation 
of histone H2A (at S1 and T119) and H3 (at T3, S10 and S28) appear 
to be hallmarks of condensed mitotic chromatin (reviewed in Mellor, 
2006 and in Peterson & Laniel, 2004). Such covalent modifications 
are performed by specific enzymatic activities which have been now 
organized into large histone acetyl transferase (HAT), histone 
deacetylase (HDAC), histone methyltransferase (HMT) and histone 
kinase families. Each member of a specific family shows a strict 
specificity for individual histone tails and for specific histone residues. 
For example, yeast and human Gcn5 and human PCAF preferentially 
acetylate lysine residues within the histone H3 amino-terminal tail, at 
K9 and K14. In contrast, the yeast and human NuA4 HAT complexes 
preferentially acetylate K4, K8, K12 and K16 of histone H4. Even 
more extreme specificity is seen with HMTs. For instance, the HMT 
Set7/9 is restricted to mono-methylation of histone H3 at K4, whereas 
the Dim-5 HMT is a tri-methylase specific for H3 K9. Thus, 
recruitment of different HATs or HMTs can result in distinct 
combinations of histone modifications. Cross-talk among different 
histone marks can also have a profound effect on enzyme activity. 
For instance, ubiquitylation of H2B K123 by the E2 ubiquitin 
conjugating enzyme Rad6 is required for subsequent di-methylation 
of H3 K4 by Set1p or H3 K79 by Dot1p. Prior histone marks can also 
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inhibit subsequent modifications. For instance, H3 S10 
phosphorylation inhibits subsequent H3 K9 methylation, and of 
course H3 K9 methylation can also block acetylation of this same 
residue. An excellent example of even more complex cross-talk is 
exemplified during p53-dependent transcriptional activation in vitro. In 
this case methylation of H4 R3 by protein arginine methyltransferase 
1 (PRMT1) stimulates CBP-p300 acetylation of H4 K5, K8, K12 and 
K16, which in turn promotes the methylation of H3 R2, R17 and R26 
by another PRMT family member, CARM1. Thus, positive and 
negative crosstalk ultimately generates the complex patterns of gene 
or locus-specific histone marks associated with distinct chromatin 
states (reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
Once a pattern of histone modifications is established at a target 
locus, what happens? Many older models proposed that histone 
modifications might directly influence either the structure of individual 
nucleosomes or the folding dynamics of nucleosomal arrays. Indeed 
one common misconception is that histone modifications that alter the 
charge of a residue, such as lysine acetylation or serine 
phosphorylation, will disrupt histone–DNA interactions leading to 
‘open’ or ‘active’ chromatin structures. There is not actually much 
evidence for such models. For example, the histone H3 tail contains 
13 positively charged amino acids, and thus acetylation of one to four 
residues will only yield a 10–30% decrease in positive charge, levels 
that are unlikely to perturb ionic interactions with DNA Consistent with 
this view, in vivo laser crosslinking studies have shown that histone 
hyperacetylation does not release tails from DNA, and nucleosomes 
that harbor >12 acetates per octamer wrap DNA normally in vitro and 
have hydrodynamic properties that are nearly identical to unmodified 
nucleosomes. Although it is true that histone hyperacetylation does 
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disrupt the folding dynamics of nucleosomal arrays in vitro, even in 
this case 6–12 acetates per nucleosome are required. Although most 
site-specific patterns of histone modifications have yet to be 
generated and tested in vitro, the prevailing view is that these histone 
marks may not alter nucleosomal dynamics by themselves (reviewed 
in Mellor, 2006 and in Peterson & Laniel, 2004). An in vivo chromatin 
fibre is actually an extremely heterogeneous nucleoprotein filament, 
even at the nucleosome level. First and foremost, in addition to 
canonical nucleosomes, in vivo chromatin arrays also contain novel 
types of nucleosome that harbour one or more variant isoforms of the 
core histones. For instance, nucleosomes assembled at yeast and 
mammalian centromeres contain a histone H3 variant, Cse4/CENP-
A, which is essential for centromere function or assembly. Another 
histone H3 variant, H3.3, replaces canonical histone H3 during 
transcription, generating a mark of the transcription event. Several 
variants of histone H2A have also been identified. In most cases, how 
histone variants alter nucleosome structure or change the folding 
properties of nucleosomal arrays is not known. It is also not clear how 
many of these variant nucleosomes are localized to specific DNA 
sequences. Notable exception, as previously stated, includes the 
deposition of H3.3 to chromatin of RNA polymerase II transcribed 
genes via a novel replication-independent assembly complex. Once a 
histone variant is targeted to a specific locus, there is the potential for 
creation of novel chromatin domains that have distinct regulatory 
properties. For instance, the amino-terminal tail of CENP-A lacks the 
phosphorylation and acetylation sites that are normally modified in 
histone H3 at transcriptionally active regions. Thus, CENP-A might 
produce islands of unmodified histone H3 that help to maintain 
centromeric chromatin in its condensed, inactive state. In contrast, 
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the histone H3.3 variant contains an amino-terminal tail that is 
virtually identical to that of histone H3, and thus it seems likely that 
many of the transcription-associated marks that have been attributed 
to histone H3 are likely also occurring on the histone H3.3 variant. 
Thus, incorporation of histone variants into chromatin fibres might 
enhance chromosome dynamics by creating domains of chromatin 
with novel properties (reviewed in Mellor, 2006 and in Peterson & 
Laniel, 2004).  
 
1.5 Controlling enzyme and code-readers substrate 
specificity 
How do the enzymes committed to modify chromatin select the 
specific target locus to be modified? The precise combination of 
locus-specific histone modifications is due to the combined effects of 
targeting histone modifying enzymes to specific loci, as well as to the 
inherent substrate specificity of the enzymes themselves. In the case 
of transcription, it is clear that targeting of histone modifications is 
achieved by direct interactions between histone modifying enzymes 
and DNA sequence-specific transcriptional regulators. For instance, 
the yeast HAT complex SAGA interacts with the transcriptional 
activation domains of a variety of yeast gene-specific activator 
proteins, and these interactions target HAT activity to specific 
promoter regions in vivo. Likewise, unliganded nuclear hormone 
receptors interact with HDAC complexes, such as NCoR and SMRT, 
which direct histone deacetylase activity to target genes and 
contribute to subsequent gene repression. In addition to targeting via 
gene-specific regulators, the yeast Set1 and Set2 HMTs are found 
associated with RNA polymerase II holoenzymes, directing histone 
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H3 K4 or K36 methylation, respectively, during transcriptional 
elongation (reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
Targeting histone modification enzymes is not unique to 
transcriptional control, as DNA repair and centromeric 
heterochromatin use distinct mechanisms to generate novel patterns 
of histone marks. In the case of DNA repair, the DNA lesion itself 
seems to play a central role in targeting histone modifications. For 
instance, the DNA damage checkpoint kinase ATM (Mec1p in yeast) 
is recruited to a DNA double strand break where it phosphorylates 
histone H2A (in yeast) or the histone H2A variant, H2AX (in 
mammals). Likewise, the human STAGA HAT complex contains DNA 
binding subunits that recognize DNA backbone-distorting base 
adducts, targeting histone H3 acetylation activity to sites of nucleotide 
excision repair (reviewed in Mellor, 2006 and in Peterson & Laniel, 
2004). 
A quite different strategy uses small noncoding RNAs to target 
histone H3 K9 methylation to chromatin surrounding mammalian and 
fission yeast centromeres. These centromeric regions are 
characterized by repetitive DNA sequences that are transcribed at 
low levels. The resulting double-stranded RNAs provide substrates 
for processing by the RNA interference (RNAi) machinery which 
produces small, 21–23 nucleotide RNAs. Recent studies have shown 
that an intact RNAi pathway is essential for targeting H3 K9 
methylation to centromeric chromatin, and furthermore that these 
small RNAs actually associate with several chromatin components. 
The resulting novel ribonucleoprotein complex ultimately targets the 
Clr4p HMT to centromeric repeats, via either RNA–RNA (nascent 
centromeric transcripts) or RNA–DNA homologous pairing. 
Subsequent histone methylation leads to recruitment of proteins such 
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as Heterochromatin Protein 1 (HP1), which directs formation of highly 
condensed, heterochromatin structures required for centromere 
function (reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
Overlaid on top of these locus-specific marks are the genome-
wide, bulk chromatin modifications that may control the day-to-day 
folding dynamics of chromosomes. For instance, newly synthesized 
histones that are deposited after passage of replication forks in S 
phase are enriched in acetylated isoforms of histones H3 and H4, 
and the formation of condensed chromosomes in mitosis is 
associated with phosphorylation of histones H3 and H2A (reviewed in 
Mellor, 2006 and in Peterson & Laniel, 2004). 
In addition to these marks linked to the cell cycle, there appears 
to be a constant battle among HATs and HDACs on a global, 
nontargeted level that maintains a baseline equilibrium level of 
histone acetylation throughout the genome. Histone deacetylase 
inhibitors, such as trichostatin A or sodium butyrate, disrupt this 
equilibrium, leading to a general increase in bulk histone acetylation. 
Such genome-wide activities of histone modifying enzymes likely act 
in concert with the cell-cycle-linked changes in bulk chromatin to 
enhance the general dynamic nature of eukaryotic chromosomes 
(reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
Anyway, targeting the enzymes or the code-reader proteins to a 
specific locus is just the first step in the process. A higher level of 
specificity must be achieved at the level of the histone tails each of 
which bears specific modifications. Therefore, a key question is how 
these simple small chemical modifications, found on relatively large 
histone proteins, make such a big difference to nuclear processes, 
particularly gene regulation. Accumulating evidence suggests that 
evolutionarily conserved domains within code-reader proteins bind to 
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certain histone modifications with very high specificity, thereby 
distinguishing the same modification at different residues, for 
example trimethylation at K4, K9, and K27. Both the sequence 
environment surrounding the methylated lysine and the distinctive 
folds in otherwise conserved domains on the reader proteins appear 
to be major determinants of site discrimination at this level. However, 
how different states of modification at one residue, such as K4, 
K4me1, K4me2, or K4me3, are discriminated is far from clear. At the 
simplest level, different domains associate with different marks. For 
example, previous work has shown that the bromodomain shows a 
high affinity for acetylated lysine, whereas the chromodomain shows 
high affinity for methylated lysine such as the plant homeodomain 
(PHD) finger that is found in a variety of proteins and regulates gene 
expression (reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
Other examples are the chromodomain containing proteins 
heterochromatin protein 1 (HP1) and polycomb that potentiate the 
formation of repressive chromatin environments via interactions with 
methylated K9 or K27, respectively. Even though lysines 9 and 27 are 
found in an identical local sequence environment (ARKS) swapping 
the chromodomains of HP1 and polycomb switches the specificity of 
the lysine that is recognized. This suggests that the chromodomains 
are involved in both binding target sites and discriminating between 
them (reviewed in Mellor, 2006). The basis of this discrimination is 
explained by the high-resolution structures of the polycomb and HP1 
chromodomains in complex with H3 peptides. These structures 
indicate that the chromodomain of polycomb distinguishes K27 from 
K9 via an extended recognition groove that binds five additional 
residues preceding the ARKS motif (Fischle et al., 2003). Members of 
the chromodomain protein (CHD) family have two chromodomain 
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motifs. In contrast to HP1 and polycomb, CHD1 shows high affinity 
for methylated K4 on active genes. Moreover, the way in which the 
CHD1 chromodomains bind to methyl-lysine is different from HP1 and 
polycomb. For HP1 and polycomb, there is a three-residue aromatic 
cage surrounding the methyl-lysine, whereas CHD1 recognition 
involves two aromatic residues. Thus, subtle differences in key 
residues within otherwise conserved protein folds coupled with the 
immediate sequence environment of the methylated lysine appear to 
determine site specificity for the chromodomain. However, the 
chromodomains appear unable to distinguish between the degree of 
methylation at their target lysine. Given that mono, di, and 
trimethylation states of K4 are found in different regions of chromatin 
(which implies that the different states of methylation are functionally 
important) other strategies or protein folds for discriminating different 
methylation states must exist. Recent work shows an extensive 
network of hydrogen bonds and complementary surface interactions 
are responsible for the unique recognition of ARTK(me3)QT in the 
histone peptide by the PHD finger. Although a K4me2 histone peptide 
has lower affinity for the PHD domain than a similar peptide 
containing K4me3, this alone does not explain how specificity for 
K4me3 is achieved in vivo, as is observed in inhibitor of growth 2 
(ING2) and bromodomain-proximal PHD finger (BPTF). The PHD 
finger in BPTF (like many PHD fingers) is found in close proximity to 
a bromodomain. Intriguingly, the histone code hypothesis predicts the 
existence of code-reader proteins with double recognition domains 
such as this PHD-bromodomain module with the potential to 
recognize combinatorial marks such as trimethylation and acetylation 
on one or multiple histone tails. As it may be too difficult to 
discriminate between me2 and me3 using a single protein fold, a 
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simpler solution might be to discriminate using a combinatorial code 
(in this case the recognition of K4me3 and acetylated lysine) and two 
different domains (the PHD and bromodomains) on the code reader. 
In this model, the NURF (nucleosome remodeling factor) complex 
that contains BPTF might be targeted to the beginning of active 
genes by the binding of the BPTF bromodomain to acetylated lysines. 
In this way, the BPTF bromodomain could influence the specificity of 
the interaction of the PHD finger with K4me3 because K4me3, like 
acetylated lysine, is concentrated at the beginning of active genes. 
The helical linker that separates the two domains could act as a 
molecular ruler, linking a particular combination of me3/acetyl marks 
to chromatin remodeling by NURF. Whether other multidomain 
proteins, with helical linkers of different lengths, recognize other 
combinations of methyl/acetyl marks remains to be determined, but it 
is a very attractive model for how different states of methylation are 
discriminated by the code readers. Also, it is clear that the biological 
function is determined not by the K4me3 mark per se, but by the 
nature of the code readers that recognize the modification (Shi et al., 
2006 and Wysocka et al., 2006). In fact, interaction between the PHD 
finger and K4me3 may also lead to the repression of active genes. 
This is the case of ING2, which in response to DNA damage, via 
K4me3, stabilizes the binding of an mSin3-HDAC1 histone 
deacetylase complex at the promoters of genes that stimulate 
proliferation, such as cyclin D1, resulting in histone deacetylation, 
repression of the active gene and, likely, tumour suppression 
(reviewed in Mellor, 2006 and in Peterson & Laniel, 2004). 
These and other observations, however, have led to the idea that 
the term “code” may be a misnomer, as it implies that a particular 
combination of histone marks will always dictate the same biological 
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function. By analogy, the genetic code is always the same no matter 
which gene is analyzed, in any cell type or tissue: TAG always means 
STOP. In the case of histone modifications, however, there are clear 
exceptions – a particular mark or set of marks can have different or 
even opposite biological consequences. Adding to the ING2 example, 
the generally inhibitory H3 K9 methylation can in some cases be 
associated with actively transcribed genes, and histone acetylation 
can be inhibitory rather than stimulatory for transcription. Thus, rather 
than a histone code there are instead clear patterns of histone marks 
that can be differentially interpreted by cellular factors, depending on 
the gene being studied and the cellular context (reviewed in Mellor, 
2006 and in Peterson & Laniel, 2004). 
 
In conclusion, histone variants, distinct patterns of 
posttranslational modifications of histones, and histone tail binding 
proteins all contribute to establishment of various ‘open’ or ‘closed’ 
chromatin domains that have specialized folding properties and 
biological functions. Some of these domains can be propagated 
through DNA replication and mitosis, guaranteeing the inheritance of 
chromatin states to progeny. Furthermore, several nonhistone 
proteins, such as HP1 or the PRC1 polycomb complex, not only bind 
to methylated histone lysines, but also recruit the methylase itself, 
thus providing a means for templating new histone methylation 
events – for example, following replication fork passage – or for 
spreading the domain to adjacent nucleosomes. How ‘open’ states 
are propagated through cell divisions is not clear, especially as 
histone lysine acetylation or serine phosphorylation can be rapidly 
reversed by HDACs or histone phosphatases. Future studies will no 
doubt continue to identify the functional and biochemical properties of 
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new chromatin domains as well as to elucidate the principles that 
govern their maintenance and propagation (reviewed in Mellor, 2006 




























2. AIM OF THE WORK – SUMMARY 
Epigenetic mechanisms leading modulation of gene expression 
are highly dynamic processes. At current stage, several data show 
the specific and numerous steps of such dynamics during the early 
stages of external stimulus-dependent gene activation. Nuclear 
receptors represent good candidates for dynamic analysis of 
epigenetic processes. However, Retinoic Acid Receptor (RAR)-
dependent epigenetic dynamics are not well elucidated. 
The present work wants to improve the knowledge of the 
dynamic epigenetic processes depending on all-trans retinoic acid 
stimulation (ATRA) on ret proto-oncogene locus during the early 
stages of transcriptional activation in a retinoid-sensitive 
neuroblastoma cell line system. We demonstrated that RARα is 
specifically bound to two regulatory regions of RET gene, the 
promoter and an upstream enhancer, in absence of its ligand. We 
also show that activation of RAR by addition of ATRA rapidly induces 
several covalent modifications to the histone tails of nucleosomes 
encompassing RET locus. Moreover, we provide evidence that such 
covalent modifications are specific for RET enhancer and promoter 
regulatory regions. Most of the chromatin modifications driving RET 
gene activation occur onto a highly methylated DNA enhancer region. 
We observed that such enhancer is methylated in tissues expressing 
and not-expression RET mRNA. Here, we show that RET enhancer 
DNA methylation in SK-N-BE cells does not inhibit activation of 
transcription per se but serves, likely, as a docking site for 
MeCP2/HDAC1/mSin3A repressive complex. Such repressive 
complex is recruited on the methylated DNA enhancer region and 
keeps RET gene silenced in absence of RAR ligand. ATRA treatment 
does not modify RARα loading on RET enhancer but induces the 
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displacement of MeCP2/HDAC1/mSin3A repressive complex from 
the enhancer region. Also, ATRA induces a specific CpG site 
demethylation which, together with the previous mechanisms, 




























In order to perform dynamic analysis of epigenetic processes 
occurring on RET locus we needed ATRA-sensitive cell line systems. 
Many evidences show that ATRA represents a differentiating-
inducing agent in neuroblastoma SK–N–BE cell line, determining up-
regulation of several genes as matrix metalloproteinase 9 (MMP-9) 
and p55 TNF receptor (Chambaut-Guerin AM et al., 1995-2000). 
Also, it has been shown that SK–N–BE cell line over-expresses RET 
mRNA upon ATRA stimulation (Tahira et al., 1991; Bunone et al., 
1995; Patrone et al., 1997). Thus, we chose SK–N–BE cell line as 
dynamic system for further analysis. 
 
3.1 All-trans retinoic acid induces RET mRNA transcription in 
SK-N-BE neuroblastoma cell line. 
To validate our system, we treated SK-N-BE cells with 1 M 
ATRA at different times (3, 6, 12 and 24 hours) and measured RET 
mRNA expression by quantitative real time PCR (Q-PCR). As 
expected, ATRA functions as a strong positive modulator of RET 
expression (Fig. 3). Maximum RET mRNA accumulation is observed 
after twelve hours of ATRA being about forty five-fold the untreated 
sample. However, mRNA accumulation is already clearly detectable 
in SK-N-BE after three hours of ATRA treatment. Also, Bunone and 
colleagues showed that induction of RET expression by retinoic acid 
occurred in the absence of de novo protein synthesis in SK-N-BE cell 
line (Bunone et al., 1995). Taken together, these findings suggest 
that RET mRNA expression could be directly driven by a retinoic acid 




3.2 RARα binds RET promoter and enhancer in vivo. 
Since ATRA specifically binds and activates Retinoic Acid 
Receptors (RARs), we asked whether ATRA treatment could 
determine a direct recruitment of RARα receptor on DNA regulatory 
regions involved in activation processes of RET transcription. We 
analyzed the upstream flanking region on RET locus (Ensemble ID: 
ENST00000355710) including the proximal promoter and a known 
enhancer region (Lang et al., 2000; Puppo et al., 2002) which is 
located about 3.5 Kbp upstream the transcription start site (TSS). We 
identified at least four putative hemi-sites for RARα binding. 
Specifically, one hemi-site is clearly enclosed in the enhancer region. 
Therefore, we checked the presence of RARα on both promoter and 
enhancer in SK-N-BE cells incubated or not with 1 M ATRA by 
chromatin immunoprecipitation (ChIP). We observed that RARα is 
bound to both RET promoter and enhancer even in absence of ATRA 
stimulation. This is in accord with other reported observations 
according to which RAR receptors may be resident on regulatory 
regions of several genes in absence of ligand (Hao et al., 2003). 
Receptor loading on RET enhancer is significantly higher than that 
observed on RET promoter (Fig. 4, lanes 1 and 5). Moreover, ATRA 
treatment does not modify RARα loading on both the regulatory 
regions (Fig. 4, lanes 2 and 6). To check whether the loading of the 
receptor was specific for both promoter and enhancer we analyzed 
an intervening DNA region localized between promoter and 
enhancer. As shown in figure 4, only a weak signal was detected for 
RARα binding onto such intervening region in absence of ATRA 
stimulation (lane 3). Rather, a slight reduction is observed when 
ATRA is added (lane 4). This data indicates RARα is found to be 
specifically bound to RET promoter and enhancer in absence of the 
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external stimulus and ATRA treatment does not modify its loading on 
promoter and enhancer regions. 
 
3.3 Effects of epigenetic drugs on RET mRNA transcription in 
SK-N-BE neuroblastoma cell line. 
We asked whether chromatin remodelling enzymatic activities 
could be involved in the process leading to activation of RET mRNA 
transcription. Therefore, we treated SK-N-BE cells with epigenetic 
drugs in order to abrogate distinct histone modifying and DNA 
methylating enzyme activities. Specifically, SK-N-BE cells were pre-
incubated  with decitabine (or deoxyazacytidine), a DNMTs inhibitor, 
and pargyline, a specific mono-amino-oxidase inhibitor (MAOi), prior 
to 1 M ATRA stimulation. As shown in figure 5a, both decitabine 
and pargyline up-regulate RET mRNA. Specifically, decitabine 
determines a two- to three-fold induction of RET mRNA. We have 
also tested decitabine in another neuroblastoma cell line, SH – SY5Y, 
and we observed a more potent RET up-regulation (data not shown). 
Interestingly, pargyline shows a remarkable effect determining a six- 
to eight-fold induction of RET mRNA. We also inhibited HDACs 
activity by trichostatine A (TSA), an unselective HDAC inhibitor 
(HDACi), but we did not obtain clear results (data not shown) since 
TSA exerts a strong pro-apoptotic effect in neuroblastoma cells 
(Subramanian et al., 2005). However, other HDACi, as sodium 
butyrate,  may induce RET up-regulation in cell lines displaying low 












Moreover, while decitabine seems to have no relevant effect on 
ATRA treatment (data not shown), pargyline enhances the effect of 
ATRA (Fig. 5b) in terms of RET up-regulation. This latter observation, 
together with the basal RET mRNA induction due to pargyline, cannot 
be explained since we have no evidence of any molecular 
mechanism involved in the process. However, these observations 
remain much interesting since pargyline, in ATRA-stimulated 
neuroblastoma cells, acts contrary to what has been largely observed 
for androgen and estrogen receptors. Also, the observed different 
responsiveness to decitabine among the two cell lines suggests the 
importance of factors, which may be missing in either cell line, 
regulating the mechanism of transcription control (see discussion). 
 
3.4 all-trans retinoic acid induces multiple epigenetic 
modifications restricted on RET promoter and enhancer. 
Since ATRA induces RET mRNA transcription soon after the  
treatment and epigenetic drug treatment modifies RET mRNA levels, 
it is likely that activation of RET transcription goes with epigenetic 
modifications. We though that such modification might occur upon 
nucleosomes encompassing RET locus. Therefore, we treated SK-N-
BE cells with ATRA at different times (0,5 – 1 – 3 – 6 hours) and 
prepared chromatin. Further, we quantitatively determined the major 
histone modifications of the histone tails of nucleosomes 
encompassing RET promoter and enhancer by coupling ChIP assays 
and Q-PCR. 
H3 Lysine 4 Methylation. We analyzed the three methylated 
form of lysine 4 on histone H3 (H3K4me, H3K4me2, H3K4me3) by 
immunoprecipitating chromatin with antibodies directed against the 
three specific modifications. We measured H3K4me2 levels on both 
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RET promoter and enhancer observing a strong decrease of the 
specific signal. Specifically, after thirty minutes of ATRA stimulation 
H3K4me2 levels are about 14% and 26% of the relative untreated 
sample chosen as reference for promoter and enhancer, respectively 
(Fig. 6a). After the sharp reduction, H3K4me2 signal slightly 
increases until the end of ATRA stimulation for both promoter and 
enhancer (Fig. 6a). We demonstrated the specificity of the observed 
process by analyzing an intervening DNA region located at half 
distance between promoter and enhancer. Figure 6a clearly shows 
the H3K4me2 signal for the intervening region was much lower than 
that observed for promoter and enhancer. Since H3K4me3 
modification is associated with the 5’ region of activated genes 
(reviewed in Mellor, 2006 and in Peterson & Laniel, 2004) we asked 
weather H3K4me2 could be methylated and transformed in H3K4me3 
or alternatively demethylated, giving H3K4me. We measured, then, 
H3K4me3 levels onto both promoter and enhancer. As expected, 
H3K4me3 signal levels on RET promoter increase soon after ATRA 
stimulation. Specifically, H3K4me3 levels increase after thirty minutes 
of ATRA treatment and maximum levels, which are three-fold the 
untreated sample, are observed at 30 and 180 minutes (Fig. 6b). 
Conversely, H3K4me3 signal on RET enhancer only slightly 
increases in respect to the untreated sample after thirty minutes of 
ATRA treatment, remaining unchanged until the end of the treatment. 
Quantitatively, H3K4me3 signal on the promoter is two-fold the 
H3K4me3 signal on the enhancer (Fig. 6b). Figure 6b clearly shows 
the H3K4me3 signal for the intervening region was much lower than 
that observed for promoter and enhancer (1 – 10 % input DNA 
values), indicating the process is specific for both the regulatory 
regions. H3K4me signal was detected predominantly on the enhancer 
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at the steady state (Fig. 6c). However, ATRA stimulation induces a 
sharp increase in H3K4me levels on both promoter and enhancer 
after 1 – 3 hours followed by a decrease at 6 hours (Fig. 6d). The 
process is not specific for the regulatory regions as we found that 
after 1 hour of ATRA treatment (but not after 30 minutes) a strong 
H3K4me signal was detectable by Q-PCR for the intervening region 
(Fig. 6d).  
H3 Lysine 27 Methylation. Methylation of histone H3 lysine 27 
(H3K27) is highly correlated with genomic silencing (Margueron et al., 
2005; Schubert et al., 2006) and, recently,  with retinoic acid signaling 
(Lee MG et al., 2007; Villa et al., 2007). Since RARα is loaded on 
both RET promoter and enhancer during the activation of RET mRNA 
transcription, we asked whether H3K27me3 was present on the 
histone tails of nucleosomes encompassing RET locus and whether 
this modification decreased after ATRA stimulation. We detected 
H3K27me3 signal on both RET enhancer and promoter in absence of 
stimulation. However, H3K27me3 signal detected on the enhancer 
was much higher than that detected on the promoter (Fig. 7a). After 
ATRA treatment, H3K27me3 levels decreased during the activation 
process both on enhancer and promoter (Fig. 7a-b). However, the 
observed reduction occurring on the enhancer is much evident than 
that observed on the promoter. The process is much more specific for 
the enhancer region than the promoter region, as the signal for the 
















H3 Lysine 9 Methylation. H3K9 methylation is usually 
associated with gene silencing (reviewed in Mellor, 2006 and in 
Peterson & Laniel, 2004). However, we found that nucleosomes 
encompassing the enhancer and the promoter regions were di-
methylated in lysine 9 in untreated samples. Quantitatively, we found 
that H3K9me2 signal on RET enhancer is two-fold higher than that 
observed on RET promoter, in absence of ATRA stimulation. Also, 
ATRA treatment induces a general increase of H3K9me2 signal, 
though the process mainly involves the enhancer region. Specifically, 
after thirty minutes of treatment, H3K9me2 signal is two-fold and four-
fold the related untreated sample for RET promoter and enhancer, 
respectively (Fig. 8a). A subsequent reduction of the signal is also 
observed (1h and 3h). While H3K9me2 signal on RET promoter 
continues decreasing until the end of the treatment, a sharp increase 
is observed on RET enhancer after six hours of ATRA stimulation 
(Fig. 8a). The observed trend for H3K4 methylation could be 
explained by a process of demethylation starting from H3K9me3 that 
leads to an enrichment of H3K9me2, followed by a further 
demethylation that leads to H3K9me and a concomitant reduction of 
H3K9me2 signal (see discussion). 
H3 Acetylation. Histone acetylation is highly associated with 
transcriptionally active chromatin (reviewed in Mellor, 2006 and in 
Peterson & Laniel, 2004). Therefore, we checked whether histone H3 
could be acetylated during the process of activation of transcription 
triggered by ATRA. We found global acetylation on both promoter 
and enhancer prior to ATRA stimulation (Fig 9). The levels of 
acetylated H3 on both regions increased rapidly in SK-N-BE cells 
after inclusion of ATRA in culture medium (Fig. 9). However, there 
were clear differences in the dynamics of H3 acetylation between 
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promoter and enhancer. In general, these modifications peaked on 
both enhancer and promoter after one hour of ATRA treatment. 
However, the enhancer signal increases more gradually than that 
observed on promoter, which, in turn, rapidly increases from 30 to 60 
minutes. This is also true for the reduction of the signal: while H3Ac 
signal decreases gradually on the enhancer, a rapid decrease is 
observed on the promoter after three hours of ATRA treatment. 
However, at six hours a peak is observed on promoter but not on the 
enhancer region (Fig. 9). 
 
Figure 10 shows the overall distribution of histone modifications 
occurring on RET locus during ATRA treatment. Every observed 
modification clearly shows specificity for distinct DNA regions which 
are involved in modulation of gene expression. Specifically, enhancer 
region is predominantly involved in demethylation of K27, while 
promoter region is predominantly involved in trimethylation of K4. 
Additionally, acetylation involves both promoter and enhancer but 
shows different kinetics depending on which regulatory region is 
observed. Moreover, all the modifications analyzed do not involve the 
intervening region (except for H3K4me), underscoring the specificity 
of the observed phenomenon and the importance of the two 
regulatory regions. 
Taken together, increasing in H3K4 tri-methylation and H3 global 
acetylation levels concomitant to H3K27 demethylation and RET 
mRNA accumulation upon ATRA treatment indicate that all-trans 
retinoic acid, likely via RARα-dependent complexes, induces 
activating epigenetic modifications on nucleosomes encompassing 










3.5 DNA methylation pattern is slightly but rapidly modified by 
all-trans retinoic acid treatment. 
Since RET locus undergoes remarkable epigenetic modifications 
on histones following ATRA treatment, we asked whether also DNA 
methylation could be involved somehow in the modulation of the 
epigenetic processes leading the activation of RET mRNA 
transcription. Therefore, we analyzed the DNA methylation profiles of 
the promoter region and the enhancer region. We collected genomic 
DNA from SK-N-BE cells and analyzed DNA methylation profiles by 
bisulfite treatment and sequencing. First, we looked at promoter 
methylation. RET promoter is embedded in a CpG island that was 
shown to be unmethylated in peripheral white blood cells (Munnes et 
al., 1998). We analyzed a region spanning from -739 to -358 in 
respect to Transcription Start Site (TSS) which likely represent the 
CpG island edge and contains 23 CpG sites. Only the more distal 
three sites were partially methylated, while the remaining sites were 
almost completely unmethylated without ATRA stimulation: observed 
promoter methylation index (MI) was 3.62% (Fig. 11). The same 
analysis was performed on the enhancer region. RET enhancer is 
localized about 3.5Kb upstream TSS. Specifically, we analyzed a 
region spanning from -3459 to -3038 which includes 10 CpG sites 
and two previously described binding sites for Pax3 and Sox10 
factors (Lang et al., 2000, 2003; Puppo et al., 2002). Figure 11 shows 
that unstimulated cells have a heavily methylated RET enhancer 
whose MI is 98,3%. These data are supported by the observation that 
the enhancer region which was analyzed in tissues expressing or not-
expressing RET, showed a lower but comparable MI of about 75% 
(data not shown). Since ATRA induces RET mRNA transcription in 
SK-N-BE cells modifying the chromatin configuration of RET locus, 
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we asked whether DNA methylation might be modified by the 
treatment as well. We stimulated SK-N-BE cells with ATRA at 
different times (6, 12, 24 hours) and analyzed promoter and enhancer 
DNA methylation profiles by bisulfite treatment and sequencing. We 
found that promoter DNA methylation is only poorly affected by ATRA 
treatment. The highest variation of promoter MI is observed after six 
hour of ATRA treatment and consists of a 1.2% reduction in respect 
of the untreated sample (Fig 11). Conversely, a more evident 
variation of MI is observed on the enhancer region after ATRA 
treatment. Specifically, the enhancer MI is reduced by 14% after 
twelve hours of treatment. However, the starting MI of the enhancer 
region is restored after twenty four hours of ATRA treatment (Fig. 11). 
We considered the observed reduction of enhancer MI a remarkable 
phenomenon to be further analyzed. However, bisulfite treatment and 
sequencing is not quantitative and may be biased by some intrinsic 
features of the technique itself. Thus, in order to quantitatively 
evaluate the MI reduction observed in SK-N-BE cells upon ATRA 
treatment we used Pyrosequencing™ technology (reviewed in 
Ronaghi, 2001 and Fakhrai-Rad, Pourmand and Ronaghi, 2002). 
Specifically, we analyzed three CpG sites in the enhancer region, 
which correspond to CpG 1 (-3455-4), 2 (-3358-7) and 3 (-3339-8) 
analyzed by cloning. We found that a specific CpG site, which is 
100% methylated in untreated samples, undergoes a 16% loss of 
methylation after six hours of ATRA treatment (MI: 84%) (Fig. 12a). 
Such MI index reduction is observed until the end of treatment (Fig. 
12a). Concomitantly, we analyzed four CpG sites on the promoter 
region, which correspond to CpG 4 (-567), 5 (-555), 6 (-539), 7 (-537) 
analyzed by cloning. As expected, DNA methylation is very low and is 
consistent with the CpG island spanning the promoter region (Fig. 
 49 
12b). Higher MI, which is 12.6%, is observed in the first CpG site 
analyzed, in absence of ATRA. This site undergoes a 2% 
demethylation upon ATRA treatment. Conversely, sites 3 and 4, 
which are unmethylated in absence of ATRA, get methylated (4% and 
1.4%, respectively) after six hours of ATRA treatment (Fig. 12b). 
However, such differences are similar to that observed for the assay 
control site, suggesting they may be background signals. 
Taken together, these findings indicate that ATRA poorly affect 
promoter DNA methylation but induces a moderate demethylation of 
a specific CpG site on RET enhancer though the overall enhancer 
DNA methylation remains remarkable. Because we cannot say this 
CpG demethylation is sufficient to contribute to activation of RET 
mRNA transcription upon ATRA stimulation, further analysis 
addressing the behaviour of transcriptional mediators depending on 
































3.6 All-trans retinoic acid induces MeCP2/HDAC1/mSin3A 
complex displacement from RET enhancer facilitating 
transcription. 
We asked whether Methylated DNA Binding Proteins (MBPs) 
might be involved somehow in the process. MBPs are generally 
associated with gene silencing, so we postulated that some MBPs 
could be involved in keeping RET gene silenced. Therefore, we 
collected chromatin from SK-N-BE cells and checked the presence of 
MBD2 and MeCP2 on both RET enhancer and promoter by 
quantitative ChIP assays.  We already knew that RET promoter was 
unmethylated and we would have not expected to find MBPs bound 
to it. In fact, we could not detect any MBD2 signal on promoter. 
However, MBD2 signal was undetectable also on the enhancer 
region (data not shown). Conversely, while we could detect only a 
very low MeCP2 signal on RET promoter, we found a remarkable 
MeCP2 signal on the enhancer region (Fig. 13a). No signal was 
detected on the intervening region (Fig 13a). These data indicates 
that MeCP2, but not MBD2, strictly binds RET enhancer but not the 
promoter region, which is embedded into an unmethylated CpG 
island. Further, we asked whether ATRA, which induces a CpG 
specific-demethylation, could determine any alteration of MeCP2 
binding on RET enhancer during the process leading RET mRNA 
transcription. We stimulated SK-N-BE cells with ATRA for sixty 
minutes and then we removed ATRA from cell culture medium, 
keeping cells in culture for additional four hours (treatment lasted 
totally 5 hours). Interestingly, MeCP2 signal decreases after five 
hours of incubation. Quantitatively, MeCP2 signal in untreated cells 
was at least five-fold the signal detected in SK-N-BE cells after five 
hours of ATRA treatment (Fig. 13b). No MeCP2 signal is detected on 
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the intervening sequence (Fig. 13b) indicating that the process is 
specific for RET enhancer. Also, since no MBPs signal has been 
detected on the intervening sequence, we think it is bona fide 
unmethylated. This data indicates that ATRA induces MeCP2 
displacement from RET enhancer concomitantly to activation of RET 
mRNA transcription. 
MeCP2 is a component of a repression complex which is often 
constituted by HDAC1 and mSin3A. First, we asked whether HDAC1 
and mSin3A were part of the complex including MeCP2. Thus, we 
checked HDAC1 and mSin3A presence on RET promoter and 
enhancer by quantitative ChIP assays. Both HDAC1 and mSin3A 
signals were found on RET enhancer (Fig. 14a-b, untreated). 
Quantitatively, HDAC1 and mSin3A signals on RET enhancer were 
comparable to that observed for MeCP2. A four-fold lower signal was 
detected for both HDAC1 and mSin3A on the promoter region (Fig. 
14a-b, untreated). These data indicate that the two repressor 
molecules are present on RET enhancer and, partially, on RET 
promoter. Also, their levels on RET enhancer are quantitatively 
comparable and this suggests the possibility they form a complex. 
Further, since ATRA treatment induces MeCP2 displacement from 
RET enhancer, we asked whether it could also modify the levels of 
HDAC1/mSin3A, thus contributing to activation of gene transcription. 
We stimulated SK-N-BE cells with ATRA as described for MeCP2 
experiments and quantitatively measured HDAC1 and mSin3A levels 
on RET enhancer. We found that both HDAC1 and mSin3A levels 








Quantitatively, a two-fold reduction is observed for both HDAC1 
and mSin3A on RET enhancer. HDAC1 and mSin3A levels on RET 
promoter behave differently: HDAC1 signal is poorly reduced but, 
interestingly, mSin3A signal rises after one hour and then decreases 
at the end of the treatment. Quantitatively, mSin3A levels are three-
fold and two-fold the levels observed in the untreated sample after 
one hour and five hours of ATRA treatment, respectively. 
Taken together, these data indicate that ATRA induces the 
displacement of MeCP2/HDAC1/mSin3A repressive complex from 
RET enhancer facilitating the concomitant activity of positive 
chromatin modifying enzymes which, in turn, leads to activation of 




















Nuclear receptors represent good candidates for dynamic 
analysis of epigenetic processes. Specifically, RAR dynamics are 
not well understood and only recent data have elucidated some 
epigenetic mechanisms involving such receptors. The recent 
findings that unliganded RAR receptors are bound to 
corepressor/histone deacetylase complexes and that, upon ligand 
addition, several histone acetylases are recruited to the receptor 
support the idea that transcriptional activation by RAR/RXR 
heterodimers coincides with an alteration of chromatin structure 
(Chen et al., 1997; Nagy et al., 1997). In addition, acetylation or 
removal of histone tails increases RAR/RXR affinity for a RARE 
assembled into a nucleosome in vitro (Lefebvre et al., 1998). 
However, besides RA-dependent promoters, acetylation of local 
histones has been reported to be concomitant to increased 
transcription in other hormone-sensitive promoters (Chen et al., 
1999; McKenna et al., 2002). 
In the present study, we show how all-trans retinoic acid 
induces rapid and dynamic epigenetic changes on RET gene 
locus, leading to activation of transcription of RET gene. 
We demonstrated that RARα is loaded on both RET promoter 
and enhancer even in absence of its ligand (Fig. 4). This is in 
accord with reported observations according to which RAR 
receptors may be resident on regulatory regions of several genes 
in absence of their agonist (Hao et al., 2003). Also, we 
demonstrated that ATRA does not increase the loading of the 
receptor on RET promoter and enhancer. However, even though 
the fraction of receptor bound to the regulatory regions remains 
unmodified, ligand binding leads to the release of nuclear receptor 
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corepressors SMRT/TRAC and NCoR/RIP13 (Horn et al., 1996; 
Nagy et al., 1999; Perissi et al., 1999), remarking the activating 
effect on transcription the retinoid may exerts by switching the 
interactors of the receptor itself.  
Abrogation of chromatin remodelling enzymatic activities by 
epigenetic drugs treatment clearly affects RET mRNA 
transcription in SK-N-BE neuroblastoma cell system (Fig. 5). 
Puppo and colleagues demonstrated that sodium butyrate, which 
is a non-specific HDACi, induces RET up-regulation in cell lines 
displaying low levels of its mRNA (Puppo et al., 2002), indicating 
that histone acetylation is mainly involved in activation of RET 
gene.  
Also, we showed that decitabine, despite its unspecific 
effects, slightly increases RET mRNA levels indicating that DNA 
methylation may play a role in modulation of RET gene 
expression. This is supported by the different responsiveness to 
decitabine we observed among SK-N-BE and another 
neuroblastoma cell line, SH – SY5Y (data not shown). In fact, 
decitabine functions as an activator of RET transcription in both 
cell lines but SH – SY5Y cells are much more sensitive than SK-
N-BE cells, being the effect of decitabine in SH – SY5Y 
comparable to that exerted by ATRA (data not shown). These 
observations suggest that this system presents a multiple level-
regulation and the two cell lines are clearly set to different levels 
of regulation. In general, SK-N-BE cells would be subjected to a 
stricter control of RET transcription, being DNA demethylation 
sufficient for SH – SY5Y, but not for SK-N-BE cells, to trigger a 
remarkable RET gene activation. We postulate such levels of 
regulation may be represented by factors, which, possibly, are 
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missing in either cell line, determining the different 
responsiveness to the demethylating agent. 
Pargyline exerts a more interesting effect determining a 
remarkable activation of RET mRNA transcription. Pargyline is a 
selective inhibitor of mono-amino-oxidases (MAO). Such 
enzymatic activities are present in many chromatin remodelling 
factors which are committed in demethylating histones. 
Specifically, the histone demethylase LSD1, which catalyzes 
demethylation of lysine 4 and 9 on histone H3, is mainly involved 
in activation of gene transcription and is inhibited by pargyline. If 
LSD1 played a key role in RET gene activation, we would have 
expected that its inhibition leads to absence of RET activation, in 
presence of ATRA. Conversely, we demonstrated that pargyline 
induces activation of RET mRNA transcription. We wonder how 
that molecule could do that and we speculated a possible 
mechanism (see below, model). As extensively stated before, 
epigenetic dynamics are highly complex and involve hundreds of 
factors. Among them, histone demethylases which have a non-
MAO demethylating activity and are not inhibited by pargyline may 
be taken into account. Specifically, histone demethylases bearing 
jmjC domain are flavo-oxidases that remove methyl groups from 
lysine 27 of histone H3 triggering activation of transcription (see 
below, model). 
Our data, together with previous observations, indicate that a 
crosstalk between activated RARα and chromatin remodelling 
factors of RET locus must exist. In fact, we demonstrated that the 
activation of RARα by ATRA treatment induces several rapid 
histone modifications (Fig. 10). 
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Histones H3 underwent a remarkable acetylation both on 
promoter and enhancer upon ATRA stimulation, indicating that a 
HAT activity is recruited. Acetylation levels are comparable for 
both the analyzed regions. However, there were clear differences 
in the dynamics of H3 acetylation between promoter and 
enhancer. In general, enhancer acetylation gradually raises and 
decreases, while promoter acetylation peaks rapidly after one 
hour and six hours of ATRA treatment. 
Histone core tails are also subject to methylation. Lysine 
methylation of H3 is generally associated with transcriptionally 
active genes (Santos-Rosa et al., 2002). Also, yeast studies have 
indicated that tri-methylated lysine of H3 is present solely on 
active genes and that the occurrence of di-methylated K4 
correlates with a poised state of chromatin, in which genes are 
either active or potentially active (Santos-Rosa et al., 2002). Our 
data are consistent with previous observations since we 
demonstrate that di-methyl-lysine 4 is present at comparable 
levels on both RET promoter and enhancer in absence of 
stimulus. ATRA induces a potent reduction of di-methyl-lysine 4 
signal on both regions and a concomitant increase of tri-methyl-
lysine 4 which mainly involve the promoter region. Taken 
together, these observations indicate that an active lysine tri-
methylation is occurring on K4 upon ATRA stimulation and the 
major effect of this process takes place on the promoter 
concomitantly to RET gene activation. 
Conversely, lysine 9 methylation is linked to gene silencing 
and generation of chromodomain-binding sites for 
heterochromatin protein 1 (Bannister et al., 2001; Santos-Rosa et 
al., 2002). Our data indicate that di-methyl-lysine 9 is present on 
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both promoter and enhancer at comparable levels. ATRA 
treatment induces specifically on RET enhancer a rapid and 
potent increase of this modification signal which gradually 
decreases and, finally, peaks again after six hours. Our findings 
are in contrast with previous observations and we cannot explain 
the phenomenon. However, we speculate that increase of di-
methyl-lysine 9 signal could depend on a demethylation from a tri-
methylated form of lysine 9 which determines a transient 
accumulation of H3K9me2. Further demethylation would explain 
the subsequent decrease of H3K9me2 signals. Performing the 
analysis with an antibody recognizing H3K9me3 may elucidate 
the process. However, as previously stated, the phenomenon is 
specific for the enhancer region, being H3K9me2 levels on RET 
promoter almost unaffected by ATRA treatment. 
Methylation of lysine 27 is also associated with gene 
silencing (Cao et al., 2002; reviewed in Swigut and Wysocka, 
2007). Specifically, E(Z)/ESC complex, also known as Plycomb 
repressive complex 2 (PRC2), methylates lysine 27 of H3 through 
the intrinsic HMTase activity of the E(Z) SET domain (Tie et al., 
2007), leading to gene silencing. On the other hand, Agger and 
colleagues identified UTX and JMJD3 as histone H3K27 
demethylases involved in activation of gene transcription (Agger 
et al., 2007). Our data are consistent with previous observations 
since we demonstrated that lysine 27 is tri-methylated upon RET 
enhancer, but not RET promoter, in absence of ATRA. Ligand 
addition induces a rapid demethylation followed by a gradual 
increase of H3K27me3 signal, which is specific for enhancer 
region and concomitant with RET gene activation. 
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Our findings also indicate that the observed processes are 
very specific for both the regulatory regions. In fact, we 
demonstrated that no signal, or at least a much lower signal, for 
any analyzed histone modification was detected in the intervening 
region, which is about 1.7Kb distant from both promoter and 
enhancer. 
Taken together, all the described histone modifications 
indicate that ATRA, likely via RAR, induces the recruitment of 
specific chromatin modifying enzymes determining H3 general 
acetylation, tri-methylation of lysine 4, tri-methyl-lysine 27 
demethylation and, bona fide, tri-methyl-lysine 9 demethylation, 
which eventually lead to gene activation. 
DNA methylation has been widely associated with gene 
silencing and one example is CpG island hypermethylation in 
cancer. CpG islands are CG reach DNA regions which are almost 
completely overlapped to gene promoters and do not present 
methylation in physiologic conditions (Bird, 2002). This is the case 
of RET gene. In fact, we showed that its promoter is completely 
unmethylated in SK–N–BE cells prior and after ATRA treatment 
(Fig. 11).  This data are supported by the observations that RET 
promoter  has been shown to be unmethylated in peripheral white 
blood cells (Munnes et al., 1998). Conversely, we showed that 
RET enhancer is heavily methylated in SK–N–BE cells. Such 
observations are supported by the analysis we performed in 
tissues expressing or not-expressing RET that showed a lower 
but comparable DNA methylation (data not shown). Besides, we 
demonstrated that ATRA treatment induce a rapid and 
quantitatively significant demethylation at CpG -3358 (Fig. 12) 
which is concomitant to RET gene activation. However, we 
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observed that CpG -3358 demethylation is specific for SK–N–BE 
cells since we found it did not occur in SH – SY5Y cells incubated 
with ATRA (data not shown). Also, SH – SY5Y cells showed an 
unmethylated promoter and a methylated enhancer which is, 
however, less methylated than RET enhancer in SK–N–BE cells 
(data not shown). 
Thus, we speculated that DNA methylation could be 
somehow involved in RET gene regulation and the enhancer 
could be the regulatory region exerting such control which is 
modulated by ATRA. This hypothesis was supported by some 
early observations: (i) RET promoter is unmethylated and the 
retinoid does not affect its methylation status (in both analyzed 
cell lines) but induces a specific CpG site demethylation on RET 
enhancer concomitantly with gene activation. (ii) ATRA induces 
RET mRNA transcription in SH – SY5Y cells. (iii) SH – SY5Y 
cells, which have a less-methylated RET enhancer, are more 
sensitive than SK–N–BE cells to demethylating agents as 
decitabine. 
Then, we theorized that RET regulation via histone 
modifications might be linked to DNA methylation. 
Methylated DNA Binding Proteins (MBPs) have been 
described as mediator of gene silencing via the recruitment of 
repressor complexes, once they bind methylated DNA. We 
demonstrated that MeCP2 specifically binds RET enhancer, but 
not RET promoter, in untreated SK–N–BE cells (Fig. 13a). In 
addition, we demonstrated that MeCP2 recruits the repressor 
molecules HDAC1 and mSin3A at RET enhancer (Fig.14) which 
likely exert their repressor activities, keeping RET gene silenced. 
These observations support our previous hypothesis according to 
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which RET enhancer exerts a key role in RET gene regulation 
being the platform that links DNA methylation to histone 
modifications. In fact, MeCP2, which binds the methylated 
enhancer region and recruits HDAC1/mSin3A, likely represents 
the link between DNA methylation and histone modifications, thus 
playing a central role in RET gene regulation in untreated SK–N–
BE cells. To strengthen our hypothesis, we demonstrated that 
ATRA induces a remarkable displacement of the repressor 
complex MeCP2/HDAC1/mSin3A from RET enhancer (Fig. 14), 
concomitantly with a specific CpG site demethylation and RET up-
regulation. Our data are consistent with the observations of 
Martinowich and colleagues (Martinowich et al., 2003) which 
report that increased synthesis of brain-derived neurotrophic 
factor (BDNF) in neurons after depolarization correlates with a 
decrease in CpG methylation within the regulatory region of the 
BDNF gene. Moreover, increased BDNF transcription involves 
dissociation of the MeCP2-histone deacetylase-mSin3A 
repression complex from its promoter (Martinowich et al., 2003).  
Other remarkable recent observations also stress the importance 
of specific and direct CpG site demethylation: consistent with 
Bruniguel’s observations (Bruniguel and Schwarts, 2003), 
Murayama and colleagues demonstrated that stimulation of 
human CD4+ T cells induces IL2 expression following epigenetic 
changes, including active demethylation of a specific CpG site, 
recruitment of Oct-1, and changes in histone modifications 
(Murayama et al., 2006). However, in our study we cannot 
distinguish whether DNA demethylation is a prerequisite for 
transcription or demethylation is merely induced by transcription, 
since, up to now, we lack observations of DNA methylation 
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patterns during the early phases of RET gene activation. 
Moreover, we do not know if demethylation is subsequent to 
MeCP2 displacement or it could directly determine the repressor 
complex displacement. To elucidate this critical phenomenon we 
are going to perform further DNA methylation pattern analysis 
during the early phases of gene activation. Much interesting 
observations by Chen and colleagues (Chen et al., 2003) indicate 
that MeCP2, which binds and silence BDNF promoter, undergoes 
phosphorylation upon physiological stimuli as neuron membrane 
depolarization concomitantly with displacement from BDNF 
promoter. Zhou and colleagues (Zhou et al., 2006) demonstrated 
that CaMKII rapidly phosphorylates MeCP2 on S421 and such 
post-translational modification determines the displacement from 
BDNF promoter. This hypothesis has been taken into account in 
our system and ATRA induced-MeCP2 post-translational 
modifications such as phosphorylation and acetylation are going 
to be checked. Confirmation of such mechanism would validate 
and extend our hypothesis according to which the enhancer 
region, via DNA methylation/MeCP2 binding, plays a key role in 
ATRA-dependent RET gene regulation. 
Finally, we propose an overall model which can be applied in 
ATRA sensitive cell systems and take into account the crosstalk 
that may exist between DNA methylation, histone modifications 
and RAR kinetics (Fig. 15). In our unstimulated system, RET gene 
is poised, showing di-methylation at lysine 4 on H3 histones 
encompassing the promoter region. However the gene is not 
expressed and the main regulatory region is the enhancer which 
binds RAR and is methylated. In absence of its ligand, RAR 
interacts with corepressors which may contribute to keep the gene 
 66 
silenced. Enhancer DNA methylation, acting as a docking site, 
allows MeCP2 to bind and recruits its reppressorial apparatus 
(HDAC1/mSin3A). Enhancer DNA methylation is crucial to 
maintain the gene silenced as MeCP2 binding is essential. A key 
role may be played by lysine 27 on H3. In an unstimulated 
system, lysine 27 on H3 is tri-methylated and this is in accord with 
the silent status of the gene. PcG is mainly involved in H3K27 
methylation and can be recruited on the enhancer. Moreover, PcG 
can directly interact with DNMTs and, therefore, may contribute 
via such recruitment, to keep the enhancer methylated which, in 
turn, will keep the gene silenced. When the retinoid is added, 
RAR undergoes a conformational change that leads to the 
displacement of the corepressors which were bound to it. ATRA 
also determines, likely via cAMP, MeCP2 phosphorylation which, 
in turn, leads to the displacement of MeCP2/HDAC1/mSin3A 
complex from the promoter. Concomitantly, a sharp reduction in 
methylation of lysine 27 and a methylation of di-methyl-lysine 4 
happen on the enhancer and promoter, respectively, shifting the 
gene status from poised to active. H3K27 demethylation likely 
depends on jmjC domain-demethylases which are specific for K27 
(UTX or JMJD3), while H3K4 methylation likely depends on SET 
domain-methyltransferases which are specific for K4 (SET1). 
ATRA also induces a specific active CpG site demethylation 
which can be read in this context as a possible mechanism to set 
a “memory” of the previous event which can facilitate further 

















5. MATERIALS AND METHODS 
5.1 Cell culture 
SK-N-BE (http://www.biotech.ist.unige.it/cldb/cl4332.html) cells 
were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 
10% foetal bovine serum (Life Technologies), 2 mM glutamine, penicillin (25 
U/mL) and streptomycin (25 µg/mL) in a 5% CO2 atmosphere at 37 °C. 
 
5.2 Chemicals and Antibodies 
All the treatments with all-trans retinoic acid (ATRA) (Sigma-Aldrich) 
were performed using a 1 µM final concentration. Trichostatine A (TSA, 
Invitrogen) pre-treatments were performed at 5 µM, 10 µM, 30 µM, 50 µM, 
100 µM and 300 µM final concentration. Pargyline (Sigma) pre-treatments 
were performed at 2 mM final concentration. Decitabine (ICN Biomedical 
Inc.) pre-treatments were performed at 10 µM and 100 µM final 
concentration. TSA and pargyline pre-treatments were three hours long while 
Decitabine pre-treatments were 48 hours long. Anti H3Ac (#06-599) antibody 
was from Upstate as well as anti di-methyl-H3K9. Anti RARα (N-20, sc-551) 
antibody was from Santa Cruz, as well as anti HDAC1 (C-19, sc-6298) and 
anti mSin3A (AK-11, sc-767). Anti mono-methyl-H3K4 (ab-8895-100), anti di-
methyl-H3K4 (ab7766-100), anti tri-methyl-H3K4 (ab8580-100) were from 
Abcam. Anti tri-methyl-H3K27 (AM-0174-200) was from Lake Placid 
Biologicals (LP BIO). 
 
5.3 Real Time RT-PCR 
Total RNA was isolated with RNeasy extraction kit (QIAGEN) according 
to the manufacturer instructions. QuantiTect Reverse Transcription kit 
(QIAGEN) was used to generate cDNA. 20 ng of cDNA for each sample was 
used as template for gene expression assays. Quantitative PCR 
amplifications were then performed using QuantiTect SYBR Green 
(QIAGEN) in a Chromo4 Real Time thermocycler (BIORAD). Following 
primers were used for RET amplifications: (forward) 5’-
ACCAGGTCTCCGTGGATG-3’ and (reverse) 5’-
CCAAGTTCTTCCGAGGGAAT-3’. Each reaction was performed in 
triplicates. Calculations of relative expression levels were performed using 
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the 2-∆∆Ct method (Livak et al., 2001) and take into account the values of 
three independent experiments. 
 
5.4 Quantitative ChIP analysis 
Cells were cross-linked by adding 1% formaldehyde for 15 minutes at 
room temperature in shaking. Glycine was added to a final concentration of 
125 mM for 5 minutes at room temperature in shaking. The cells were then 
rinsed twice with cold PBS supplemented with 500 µM PMSF and harvested 
in five pellet-volumes of Cell Lysis Buffer (5 mM PIPES pH 8.0, 85 mM KCl, 
0.5% NP40)) supplemented with 1 mM PMSF and Complete™ protease 
inhibitors mix (Roche). Lysates were incubated for 30 minutes at 4 °C and 
then passed through ten dounce cycles. They were subsequently centrifuged 
and nuclei were collected. Nuclei were then resuspended in 250 µL 
Sonication Buffer (0.3% SDS, 10 mM EDTA, 50 mM Tris-HCl ph 8.0) 
supplemented with with 1 mM PMSF and Complete™ protease inhibitors mix 
(Roche) and incubated for 45 minutes at 4 °C. Chromatin was sonicated to 
an average DNA length of 400-800 bp using a 3 mm (small size) tip equipped 
Bandelin Sonoplus UW-2070 sonicator with 7 X 15 seconds cycles of pulses 
(specific cycle 0.3, Power 30%) alternated by 60 seconds of rest. Sonicated 
samples were centrifuged and the supernatant was collected. 80 µg of 
chromatin were diluted with Dilution Buffer (0.01% SDS, 1.2 mM EDTA, 16.7 
mM Tris-HCl pH 8.0), precleared by incubation with 20 µL Salmon Sperm 
DNA/Protein A Agarose-50% Slurry (#16-157, Upstate) and subjected to 
immunoprecipitation with specific antibodies with rotation over-night at 4 °C. 
Immunocomplexes were collected by adsorption onto 30 µL Salmon Sperm 
DNA/Protein A Agarose-50% Slurry (#16-157, Upstate) and the beads were 
washed sequentially with Low Salt Washing Buffer (0.1% SDS, 2mM EDTA, 
20 mM Tris-HCl pH 8.0, 1% Triton X-100, 150 mM NaCl) (4 times), High Salt 
Washing Buffer ((0.1% SDS, 2mM EDTA, 20 mM Tris-HCl pH 8.0, 1% Triton 
X-100, 500 mM NaCl) (4 times) and LiCl Washing Buffer (#20-156, Upstate). 
Precipitates were washed with TE Buffer (10 mM Tris-HCl pH 8.0 and 1 mM 
EDTA), and antibody-chromatin fragments were eluted from the beads with 
1% sodium dodecyl sulphate in 0.1 M NaCO3. Cross-links were reverted by 
adding 200 mM NaCl and heating at 65 °C overnight. 40 mg/mL RNase A 
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and 20 mg/mL proteinase K, 10 mM EDTA and 40 mM Tris-HCl pH 6.5 were 
added and samples were then incubated 2 hours at 45 °C. Samples were 
then extracted in phenol-chloroform-isoamylic acid (25:24:1), ethanol-
precipitated and finally centrifuged for 45 minutes at 4 °C. Air-dry pellet was 
resuspended in 60 µL of H2O and 2 µL of each sample were used as 
template. Input DNA was the unbound fraction of the non-
immunoprecipitated sample (NoAb). Proper dilutions were set in order to get 
a standard curve for absolute quantification. Following primers were used for 
amplification: enhancer region (forward) 5’-CACCGACCACTTTGCTAACAG-
3’ and (reverse) 5’-GGTGGTTGGAAGCACAGACT-3’; intervening region 
(forward) 5’-AGGAGCACAGCCCCAGAT-3’ and (reverse) 5’-
GCCCTTGGCTGACATTGA-3’; promoter region (forward) 5’-
TTACGTGCGGAGAGTTCTGTT-3’ and (reverse) 5’-
CTGAGCGGGAAAAGGAAAC-3’. Each ChIP assay was performed at least 
on three independent occasions.  
 
5.5 DNA methylation analysis 
Genomic DNA was isolated with DNeasy extraction kit (QIAGEN) 
according to the manufacturer instructions. Up to 2 µg of genomic DNA were 
bisulfite-treated with EZ DNA Methylation Kit (ZYMO RESEARCH) and 
eluted in 30 µL of H2O. 2 µL of each sample were used as template in PCR 
reactions. HotStar Taq DNA Polymerase (QIAGEN) was used in the PCR 
reaction to avoid possible room temperature mispriming. 
DNA methylation patterns: PCR products were cloned with pGEM-T-
Easy Kit (Promega) according to the manufacturer instructions. Ligations 
were transformed in supplied competent cells. Colonies were screened by 
PCR colony protocol and positive clones were cultured for further plasmidic 
DNA collection. Plasmids were isolated with NocleoSpin Kit (Macherey-
Nagel) and subsequently sequenced for analysis of DNA methylation 
patterns. 
Pyrosequencing™ analysis: bisulfite-treated genomic DNA was 
amplified with the following pyrosequencing-specific primers: promoter 
(biotinylated-forward) 5’- GAGAGTTTTTTTGTGTAAGGGATGTAAGGG-3’, 
(reverse) 5’- CCCACTTACAATCCCTACCTTTTACCCTTTCC-3’, 
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(sequencing) 5’- TTTTTTTGTTTGTTTTTTT-3’; enhancer (forward) 5’- 
AGTGGTAGATAGATGGGAAATTGA-3’, (biotinylated-reverse) 5’- 
ACCCAACTCCATCCTAATAATACT-3’, (sequencing 1) 5’- 
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